5/22/15, 7:02 AM
NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing non-antibiotic anti-infective products ("NovaBay"), today announced that it has entered into a securities purchase agreement for the sale of $6,863,000 of its common stock and warrants to purchase common stock in a private placement.
Investors have agreed to purchase 10,893,648 units consisting of one share of NovaBay common stock and a warrant to purchase an additional one-half share of common stock. The cost per unit is $0.63. The warrants, totaling rights to 5,446,824 shares, exercisable beginning on the date six months after the date of issuance, entitle the holders to purchase one share of common stock at a price of $0.78 per share, and include a provision for forced conversion if the common stock trades at or above $1.00 for 10 out of 20 consecutive trading days. This warrant will expire, unless exercised, 18 months following the date of issuance. If fully exercised, these warrants would bring approximately $4.2 million of gross proceeds to NovaBay. The closing of the private placement is subject to the satisfaction of customary closing conditions. The offering is expected to close on or about May 22, 2015, subject to customary closing conditions.
China Kington Investment Co Ltd acted as the sole placement agent of the offering, with Maxim Group LLC acting as financial advisor to NovaBay. Eric Wu, Executive Director of China Kington Investment, commented on the private placement by affirming his company's support for NovaBay. "We are optimistic about NovaBay's future prospects through its ability to establish a large sales network and grow its market share in the global eye care market. We also believe that NovaBay has the potential to become a leading pharmaceutical company in Asia with its partner China Pioneer Pharma. We plan to be the company's long-term financial partner to support these goals."
NovaBay intends to use the net proceeds from this offering for working capital and general corporate purposes, including research and development, clinical trials and selling, and general and administrative expenses, including sales and marketing expenses related to launching its Avenova™ product across the U.S.
The foregoing securities were offered in the private placement and have not been registered under the Securities Act of 1933, as amended, or under applicable state securities laws. Accordingly, these securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. As part of the transaction, NovaBay has agreed to file a registration statement with the Securities and Exchange Commission for purposes of registering the resale of (i) the shares of common stock sold to the investors, and (ii) the common stock issuable upon the exercise of the warrants.
This notice is issued pursuant to Rule 135c under the Securities Act and does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state. Any offering of the securities under the resale registration statement will only be by means of a prospectus.
Write to editorial@benzinga.com with any questions about this content. Subscribe to Benzinga PRO: http://pro.benzinga.com
© 2015 Benzinga Newswires. Benzinga does not provide investment advice. All rights reserved.
Recent NBY News
- NovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova Sales • Business Wire • 04/22/2024 10:57:00 AM
- NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder Equity • Business Wire • 04/19/2024 10:00:00 PM
- NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses • Business Wire • 04/17/2024 10:59:00 AM
- NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results • Business Wire • 03/26/2024 08:05:00 PM
- NovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Conference Call on March 26, 2024 • Business Wire • 03/25/2024 10:38:00 PM
- NovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment; Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023 • Business Wire • 03/14/2024 12:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:52:33 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 04:52:28 PM
- NovaBay Pharmaceuticals Reports 64% Year-Over-Year Growth in Avenova Unit Subscription-Based Sales • Business Wire • 01/30/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2024 01:00:12 PM
- NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma’s Extensive Distributor Network • Business Wire • 01/09/2024 02:15:00 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 01/04/2024 04:50:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 12:58:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 09:32:03 PM
- NovaBay Pharmaceuticals Partners with Woo University to Educate Eyecare Professionals on the Use of Amniotic Membranes • Business Wire • 12/06/2023 11:50:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:10:51 PM
- NovaBay Pharmaceuticals Reports Third Quarter 2023 Financial Results • Business Wire • 11/09/2023 09:05:00 PM
- NovaBay Pharmaceuticals to Hold Third Quarter 2023 Conference Call on November 9, 2023 • Business Wire • 11/02/2023 10:50:00 AM
- NovaBay Pharmaceuticals Expands Physician Dispensed Sales Channel with New Avenova Programs • Business Wire • 10/11/2023 12:00:00 PM
- NovaBay Pharmaceuticals to Present at the Dawson James Small Cap Growth Conference • Business Wire • 10/02/2023 10:50:00 AM
- Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference • GlobeNewswire Inc. • 09/21/2023 01:35:00 PM
- NovaBay Pharmaceuticals Announces Commercial Launch of Avenova® Allograft • Business Wire • 09/14/2023 12:00:00 PM
- NovaBay Pharmaceuticals Announces Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova® Allograft • Business Wire • 09/11/2023 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/10/2023 08:47:15 PM
- NovaBay Pharmaceuticals Reports Second Quarter 2023 Financial Results • Business Wire • 08/10/2023 08:05:00 PM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM